Despite COVID-19, we are operating at full capacity and all project work is operating as usual.

Clinically predictive preclinical efficacy testing services at your disposal

JULY 9, 2015

Pharmatest Services Ltd participates Tumor Models event in Boston

Pharmatest Services Ltd attends Tumor Models event of Hanson Wade held in Boston, MA, USA, on July 21 – 23. Pharmatest has a sponsored talk and three poster presentations in the event, and welcomes everyone to visit our booth.

Pharmatest Services Ltd (Pharmatest) is a contract research organization that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. The Tumor Models events organized by Hanson Wade enable the preclinical oncology community to come together and uncover emerging next generation models that will enhance their preclinical strategies.

Pharmatest attends Tumor models event with the following scientific presentations:

-       Sponsored talk by Dr. Sanna Käkönen (consultant for Pharmatest from Aurexel) on Thursday, July 23 at 10.20 am: “Breaking the morbid bond – Identifying compounds to silence the vicious crosstalk between tumor and bone microenvironment utilizing bone metastasis models”

-       Poster presentation by Dr. Johanna Tuomela: “Establishment of realistic patient-derived preclinical models for prostate cancer bone metastasis”

-       Poster presentation by Dr. Jenni Bernoulli: “Radium-223 dichloride exhibits dual mode-of-action inhibiting both tumor and tumor-induced bone growth in two osteoblastic prostate cancer models”

-       Poster presentation by Dr. Jenni Bernoulli: “Novel luciferase labeling technique to improve imaging of orthotopic pancreatic cancer model”


If you would like to meet our representatives during the meeting, click here.